Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease

INTRODUCTION: Therapeutic options are critically needed for children with refractory very early onset inflammatory bowel disease (VEO-IBD). Our aim was to evaluate clinical response to canakinumab, an anti-IL-1β monoclonal antibody, in patients with VEO-IBD whose phenotype resembles those with monog...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaul, Eliana, Conrad, Máire A., Dawany, Noor, Patel, Trusha, Canavan, Megan C., Baccarella, Alyssa, Weinbrom, Sarah, Aleynick, Daniel, Sullivan, Kathleen E., Kelsen, Judith R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531243/
https://www.ncbi.nlm.nih.gov/pubmed/36203564
http://dx.doi.org/10.3389/fimmu.2022.972114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531243/
https://www.ncbi.nlm.nih.gov/pubmed/36203564
http://dx.doi.org/10.3389/fimmu.2022.972114

Ejemplares similares